DOI: 10.21276/ajptr
Fri, 22 Mar 2019

Tigecycline : First Member of the Novel Glycylcycline Class of Extended-Spectrum Antibiotics

Arathi S Nair 1,Bushra Abdul Rahim1,Aleena Francis1, Limi Joseph Gomez1  , Soumya R. V* ,A. S William Arputha Sundar1 I John Wesly1

1. Department of pharmacy practice, Sree Krishna College of Pharmacy And Research Centre , Thiruvananthapuram, Kerala, India


ABSTRACT

Tigecycline is the first member of a synthetic analogue of tetracycline, known as a glycylcyline. Like other tetracyclines, tigecycline is a broad spectrum bacteriostatic agent. It inhibits protein synthesis by binding to the bacterial 30S ribosomes. Tigecycline has activity against both gram-positive and gram-negative bacteria. It also has activity against many multidrug resistant organisms including methicillin-resistant Staphylococcus aureus (MRSA), Pencillin-resistant Step to coccus pneumonia (PRSP) Vancomycin resistant Enterococcus species (VRE) and extended- spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiellapneumoniae. Tigecycline was approved for use in the United States in 2005.It is currently indicated inpatients 18 year of age and older for the treatment of complicated skin and skin structure infections and intra-abdominal infections due to sensitive organisms. Tigecycline is available in vials of 50 mg for parenteral use under the brand name Tygacil. The recommended dose is 100 mg intravenously initially, followed by 50 mg every 12 hours for 5 to 14 days depending on the severity and site of the infection. The Food and Drug Administration had issued a black box warning due increased risk for death in patients who received tigecycline with certain severe infections. The increased mortality rate is associated with patient who treated for hospital-acquired pneumonia, particularly ventilator-associated pneumonia. The cause of excess deaths is uncertain, but it is likely that most deaths related to the progression of the infection. A reduced dosage is recommended for patients with severe underlying liver disease.

Keywords: Tigecycline, Broad spectrum antibiotic; multi-resistant pathogens, Black box warning


[PDF]   Viewed: 49   Downloaded: 25 DOI No: 10.21276/ajptr.2018.08.06.17
  • Call for paper

    American Journal of PharmTech Research (AJPTR) is a peer-reviewed, bimonthly official international journal allowing access to abstracts and full-text.

    Read more...

     

  • Email & SMS Alerts

    Email/SMS alert system is one of the key features and gives update information about the submitted manuscript.

    Read more...

  • Article Statastics

    American Journal of PharmTech Research (AJPTR) provides unique facility for authors to know popularity of articles on basis of numbers of PDF download and views. It will display in tabulated format.

  • Online Submission

    American Journal of PharmTech Research (AJPTR) is one of the International open access journal devoted to various disciplines in science and technology.

    Read more...

web counter
web counter